HEMODIALYSIS-ASSOCIATED DYSLIPIDEMIA: EFFECT OF VIRGIN ARGANE OIL CONSUMPTION

Background and Aims: Most Hemodialysis patients suffer from dyslipidemia-associated cardiovascular events. Targeting blood lipids with Virgin Argane Oil consumption as a lipid-modulatory mean is the scope of the present study.

Methods: Among 86 patients of our hemodialysis facility, 47 patients were eligible and were randomly assigned to either control group or to Argane Oil consumption group during 5 weeks study. Clinical and blood biochemistry exams were obtained before and after Argane Oil consumption.

Results: Most hemodialysis patients included in the present study have dyslipidemia. They have, respectively, 95.55%, 51.11% and 53.33%, low blood levels of HDLc, high triglycerides and high LDLc blood levels. Furthermore, between 79.54% and 89.47% of patients have high lipid atherogenic incides. When compared to control group of patients, those who were on Argane Oil treatement for five weeks experienced a statistically significant decrease of LDLc and apolipoprotein B, and an increase of HDLc. Furthermore, when compared to control group, argane oil consumption induced an important and statistically significant decrease of all lipid atherogenic indices.

Conclusion: Consumption of Virgin Argane oil is safe and efficient to positively modulate blood lipids in hemodialysis patients with dyslipidemia. Results of the present clinical study support the daily consumption of Virgin Argane Oil as a practical application against dyslipidemia-associated cardiovascular and cerebrovascular complications.